Scynexis, Inc., a biotechnology company, announced the closing of its previously announced exclusive license agreement with GSK plc to commercialize the novel antifungal Brexafemme (ibrexafungerp tablets) as a treatment for vulvovaginal candidiasis (VVC) and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases.
Under the terms of the agreement, GSK will make an upfront payment to Scynexis of $90 million, plus additional potential milestone-based payments totalling up to $503 million. GSK will also pay mid-single digit to mid-teen digit tiered royalties on the totality of sales across all indications. Further information regarding the financial terms of the agreement can be found in Scynexis
